The Trump administration is already gearing up for another round of Medicare drug price negotiations, while OpenAI launched a new evaluation tool.

Senate Democrats and the Biden administration dropped plans to set drug price caps based on the amount paid in other high-income countries, during talks years ago to push through the law that empowered Medicare to negotiate down the cost of prescription medications.

CMS draft expands drug price talks to include Medicare Part B drugs and outlines steps for future renegotiations; public comments due by June 26.

The executive order directs Trump's administration to take actions against "discriminatory" policies in foreign countries that suppress drug prices.

President Trump on Monday called on drugmakers to lower their prices within the next month to be closer to those charged in other high-income countries, threatening to subject them to steep caps on how much they can earn from Medicare if they fail to do so.

Delaying Medicare’s ability to negotiate prices on small-molecule drugs until 13 years after FDA approval will decrease the amount of Medicare spending subject to price negotiation by billions of dollars annually.

As he launches a North American stadium tour and his "Hurry Up Tomorrow" film, Abel Tesfaye reflects on losing his voice onstage in 2022 and his decision to stop using his longtime stage name of The Weeknd. (May 7) The days of unlimited Medicare prescription drug costs are finally over.

President Trump will introduce a "most favored nation" plan aimed at cutting Medicare drug prices by linking them to the prices of medication abroad, sources told CBS News.

Conflicting QSSD definitions from two federal agencies mean that CMS’ administrative authority on drug pricing and payment is not well aligned with FDA’s authority to regulate drug safety and efficacy.